OAR 333-333-2120: Psilocybin Product Delivery Methods

(1) A manufacturer must design and manufacture all psilocybin products to be consumed by a client orally or delivered via another enteral method (2) A manufacturer is prohibited from designing or manufacturing psilocybin products that can be delivered to clients through any method other than orally or another enteral method. A manufacturer is prohibited from designing or manufacturing psilocybin products that include but not limited to, transdermal patches, inhalers, nasal sprays, suppositories and injections.